EA201270767A1 - Терапия на основе лигандов хемосенсорных рецепторов - Google Patents
Терапия на основе лигандов хемосенсорных рецепторовInfo
- Publication number
- EA201270767A1 EA201270767A1 EA201270767A EA201270767A EA201270767A1 EA 201270767 A1 EA201270767 A1 EA 201270767A1 EA 201270767 A EA201270767 A EA 201270767A EA 201270767 A EA201270767 A EA 201270767A EA 201270767 A1 EA201270767 A1 EA 201270767A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ligands
- receptors
- chemosensor
- therapy
- basis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Abstract
Изобретение включает способы лечения диабета, ожирения и других метаболических заболеваний, нарушений или патологических состояний с участием лигандов хемосенсорных рецепторов. Также данная заявка включает композиции лигандов хемосенсорных рецепторов и их приготовление для применения в способах по настоящему изобретению.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/763,926 US9901551B2 (en) | 2009-04-20 | 2010-04-20 | Chemosensory receptor ligand-based therapies |
PCT/US2010/053257 WO2011133180A1 (en) | 2010-04-20 | 2010-10-19 | Chemosensory receptor ligand-based therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201270767A1 true EA201270767A1 (ru) | 2013-06-28 |
Family
ID=44834962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201270767A EA201270767A1 (ru) | 2010-04-20 | 2010-10-19 | Терапия на основе лигандов хемосенсорных рецепторов |
Country Status (14)
Country | Link |
---|---|
US (1) | US9901551B2 (ru) |
EP (1) | EP2560660A4 (ru) |
JP (1) | JP5907952B2 (ru) |
KR (1) | KR101881608B1 (ru) |
CN (2) | CN106039313A (ru) |
AR (1) | AR078678A1 (ru) |
BR (1) | BR112012026838A2 (ru) |
CA (1) | CA2800470A1 (ru) |
EA (1) | EA201270767A1 (ru) |
IL (1) | IL222586A0 (ru) |
MX (1) | MX2012012157A (ru) |
SG (3) | SG184935A1 (ru) |
WO (1) | WO2011133180A1 (ru) |
ZA (1) | ZA201208277B (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9757346B2 (en) | 2008-09-03 | 2017-09-12 | Volant Holdings Gmbh | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
WO2012054530A2 (en) * | 2010-10-19 | 2012-04-26 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
BR112013009635A2 (pt) | 2010-10-19 | 2016-07-12 | Elcelyx Therapeutics Inc | terapias à base de ligante de receptor quimiossensorial |
EP2629773A2 (en) * | 2010-10-19 | 2013-08-28 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
BR112013017411B1 (pt) | 2011-01-07 | 2022-03-22 | Anji Pharma (Us) Llc | Uso de uma composição compreendendo metformina ou um sal da mesma |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US10195136B2 (en) * | 2011-08-24 | 2019-02-05 | Avon Products, Inc. | Collagen and elastin stimulating compositions and uses thereof |
AU2012363873B2 (en) | 2012-01-06 | 2017-11-23 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
EA033067B1 (ru) | 2012-01-06 | 2019-08-30 | Элселикс Терапьютикс, Инк. | Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
WO2016205754A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
WO2016205701A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Enteral fast access tract platform system |
JP6777632B2 (ja) * | 2015-07-27 | 2020-10-28 | サントリーホールディングス株式会社 | 環状ジペプチド及び甘味料を含有する組成物 |
EP3568411B1 (en) * | 2017-01-13 | 2024-03-06 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
US20210084956A1 (en) * | 2018-02-23 | 2021-03-25 | Ambra Bioscience Llc | Compositions and methods for hunger control and weight management |
US10737259B2 (en) * | 2018-08-31 | 2020-08-11 | Pall Corporation | Salt tolerant anion exchange medium |
US20210361651A1 (en) * | 2020-05-06 | 2021-11-25 | Corcept Therapeutics Incorporated | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators |
KR20230124020A (ko) | 2020-12-21 | 2023-08-24 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 피리미딘 시클로헥실 글루코코르티코이드 수용체 조절제의제조 방법 |
CN115252630B (zh) * | 2022-09-02 | 2024-02-09 | 深圳技术大学 | 黄柏酮在制备预防、改善或治疗非酒精性脂肪肝的药物中的应用 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
JPS58403B2 (ja) | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L− アスコルビンサンセイザイノ セイゾウホウ |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
JPS5825980B2 (ja) | 1976-02-12 | 1983-05-31 | ヤマサ醤油株式会社 | サイクリックヌクレオチドの定量法 |
US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
JPS62195323A (ja) | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | 胃内滞留型粒子 |
US4915952A (en) | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
JP3249147B2 (ja) * | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | 生理活性蛋白含有経口製剤 |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
JPH06509702A (ja) | 1991-04-05 | 1994-11-02 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 匂い物質受容体およびその使用 |
DE69206993T2 (de) | 1991-07-19 | 1996-05-30 | Uniroyal Chem Co Inc | Zusammensetzungen zur verwendung von filmen auf saatgut |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
ATE173159T1 (de) | 1992-03-25 | 1998-11-15 | Depomed Systems Inc | Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
US5322697A (en) | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
FR2704146B1 (fr) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules d'acide acétylsalicylique à libération contrôlée. |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5589194A (en) | 1993-09-20 | 1996-12-31 | Minnesota Mining And Manufacturing Company | Method of encapsulation and microcapsules produced thereby |
US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
IL108205A0 (en) | 1993-12-28 | 1994-04-12 | Yeda Res & Dev | Olfactory genes and receptors |
US5691188A (en) | 1994-02-14 | 1997-11-25 | American Cyanamid Company | Transformed yeast cells expressing heterologous G-protein coupled receptor |
IT1270216B (it) | 1994-06-14 | 1997-04-29 | Recordati Chem Pharm | Metodo di stabilizzazione di composti biologicamente attivi mediante microgranuli ricoperti sospendibili in fluidi alimentari |
JP3350054B2 (ja) | 1994-07-08 | 2002-11-25 | アストラゼネカ・アクチエボラーグ | 複数単位の錠剤化された剤形▲i▼ |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
AU1118197A (en) | 1995-11-09 | 1997-05-29 | Johns Hopkins University School Of Medicine, The | Novel sperm receptors |
CN1125574A (zh) | 1995-11-10 | 1996-07-03 | 邵洪 | 肠溶谷氨酰胺 |
GB9523752D0 (en) | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US5874243A (en) | 1997-03-28 | 1999-02-23 | Smithkline Beecham Corporation | OLRCC15 receptor |
US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
PT998271E (pt) | 1997-06-06 | 2005-10-31 | Depomed Inc | Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis |
EP1003476B1 (en) | 1997-08-11 | 2004-12-22 | ALZA Corporation | Prolonged release active agent dosage form adapted for gastric retention |
US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
US6538194B1 (en) | 1998-05-29 | 2003-03-25 | Catalysts & Chemicals Industries Co., Ltd. | Photoelectric cell and process for producing metal oxide semiconductor film for use in photoelectric cell |
FR2780405B1 (fr) | 1998-06-25 | 2001-12-28 | Centre Nat Rech Scient | Nouveaux recepteurs olfactifs et leurs utilisations |
TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
GB2354761A (en) | 1999-09-28 | 2001-04-04 | British Sugar Plc | Preparation of benzoyloxy acetic acid derivatives |
US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
EP1125507A1 (en) | 2000-02-15 | 2001-08-22 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Inulin products with improved nutritional properties |
WO2001077676A1 (en) | 2000-04-07 | 2001-10-18 | Senomyx, Inc. | T2r taste receptors and genes encoding same |
TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
AU2001296196B2 (en) | 2000-10-25 | 2006-07-06 | Metcon Medicin Ab | New composition and method for the treatment of dysglucaemia |
US6955887B2 (en) | 2001-03-30 | 2005-10-18 | Senomyx, Inc. | Use of T1R hetero-oligomeric taste receptor to screen for compounds that modulate taste signaling |
US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
US6893627B2 (en) | 2001-08-31 | 2005-05-17 | Rutgers, The State University Of New Jersey | Method for treating type 2 diabetes with an extract of Artemisia |
DE10226203B4 (de) | 2002-06-13 | 2008-04-03 | Südzucker AG Mannheim/Ochsenfurt | Kondensierte Palatinose, Verfahren zu deren Herstellung und deren Verwendung |
WO2004004690A1 (en) * | 2002-07-03 | 2004-01-15 | Abbott Laboratories | Liquid dosage forms of proton pump inhibitors |
US7670627B2 (en) | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
ZA200508355B (en) | 2003-05-28 | 2007-03-28 | Unilever Plc | Satiety enhancing food products |
CA2524439A1 (en) | 2003-05-28 | 2004-12-09 | Unilever Plc | Satiety enhancing food products |
US20050038415A1 (en) | 2003-08-06 | 2005-02-17 | Rohr William L. | Method and apparatus for the treatment of obesity |
US20050244810A1 (en) | 2003-09-29 | 2005-11-03 | Egan Josephine M | Taste signaling in gastrointestinal cells |
EP1677780A4 (en) | 2003-10-16 | 2007-05-02 | Univ California | DIETETIC COMPOSITIONS AND OTHER COMPOSITIONS, COMPOUNDS AND METHODS FOR ORGANIC LIPID REDUCTION, APPETILE CONTROL, AND METABOLISM MODULATION OF FATTY ACIDS |
AU2005219372A1 (en) * | 2004-02-13 | 2005-09-15 | Safeway Investments Ltd. | Therapeutic calcium phosphate particles and methods of making and using same |
WO2006086727A2 (en) * | 2005-02-09 | 2006-08-17 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
JP5114381B2 (ja) | 2005-03-31 | 2013-01-09 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 精神疾患および障害治療用アミリンおよびアミリンアゴニスト |
JP2008540437A (ja) | 2005-05-03 | 2008-11-20 | ミユーチユアル・フアーマシユーチカルズ・カンパニー・インコーポレーテツド | キニーネを含有する制御放出調合剤 |
AU2007209357A1 (en) | 2006-01-25 | 2007-08-02 | Vib Vzw | Method to control body weight |
WO2008008224A2 (en) | 2006-07-10 | 2008-01-17 | Duke University | Sour taste receptor compositions and methods |
WO2008031439A2 (en) | 2006-09-15 | 2008-03-20 | Stevia Aps | Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo [ 3.2. i ]octans such as steviol and isosteviol |
US20080107787A1 (en) | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | Anti-Diabetic Composition with High-Potency Sweetener |
CN100490789C (zh) | 2006-12-22 | 2009-05-27 | 北京亚东生物制药有限公司 | 一种治疗癌症的中药肠溶胶囊剂的用途 |
US20080274215A1 (en) * | 2007-05-03 | 2008-11-06 | Northern Holdings Inc. | Composition for treatment of cold and flu |
US20080305500A1 (en) | 2007-06-08 | 2008-12-11 | Senomyx, Inc. | Novel cell-based assays for identifying enhancers or inhibitors of t1r taste receptors (t1r2/t1r3 sweet) and umami (t1r1/t1r3 umami) taste receptors |
US20080306076A1 (en) | 2007-06-08 | 2008-12-11 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
US20080311192A1 (en) * | 2007-06-12 | 2008-12-18 | Kraft Foods Holdings, Inc. | Enteric-Coated Glucosinolates And Beta-Thioglucosidases |
EP2197433A4 (en) | 2007-08-20 | 2010-09-08 | Sinai School Medicine | REGULATION OF GLP-1 AND SGLT-1 IN GASTROINTESTINAL CELLS |
WO2009049105A2 (en) | 2007-10-09 | 2009-04-16 | Gelesis, Inc. | Methods for inducing satiation |
US8063250B2 (en) | 2007-11-26 | 2011-11-22 | Teva Pharmaceutical Industries, Ltd. | Crystal forms of O-desmethylvenlafaxine fumarate |
WO2010027498A2 (en) | 2008-09-03 | 2010-03-11 | New Science Holdings, Llc | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
MX2011010192A (es) | 2009-04-03 | 2011-10-17 | Dms Ip Assets B V | Composicion que induce saciedad. |
AR076341A1 (es) * | 2009-04-20 | 2011-06-01 | Elcelyx Therapeutics Inc | Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion |
DE102009027744A1 (de) | 2009-07-15 | 2011-01-20 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Prekursor-Verbindungen von Süßrezeptor-Antagonisten zur Prävention oder Behandlung von Krankheiten |
-
2010
- 2010-04-20 US US12/763,926 patent/US9901551B2/en not_active Expired - Fee Related
- 2010-10-19 EP EP10850399.6A patent/EP2560660A4/en not_active Withdrawn
- 2010-10-19 SG SG2012077558A patent/SG184935A1/en unknown
- 2010-10-19 KR KR1020127030417A patent/KR101881608B1/ko active IP Right Grant
- 2010-10-19 SG SG10201503098PA patent/SG10201503098PA/en unknown
- 2010-10-19 EA EA201270767A patent/EA201270767A1/ru unknown
- 2010-10-19 WO PCT/US2010/053257 patent/WO2011133180A1/en active Application Filing
- 2010-10-19 CN CN201610342910.7A patent/CN106039313A/zh active Pending
- 2010-10-19 BR BR112012026838A patent/BR112012026838A2/pt not_active IP Right Cessation
- 2010-10-19 SG SG10201909796P patent/SG10201909796PA/en unknown
- 2010-10-19 AR ARP100103817A patent/AR078678A1/es unknown
- 2010-10-19 CA CA2800470A patent/CA2800470A1/en not_active Abandoned
- 2010-10-19 CN CN201080067558.1A patent/CN102946885B/zh not_active Expired - Fee Related
- 2010-10-19 MX MX2012012157A patent/MX2012012157A/es active IP Right Grant
- 2010-10-19 JP JP2013506126A patent/JP5907952B2/ja active Active
-
2012
- 2012-10-21 IL IL222586A patent/IL222586A0/en unknown
- 2012-11-05 ZA ZA2012/08277A patent/ZA201208277B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR101881608B1 (ko) | 2018-07-24 |
MX2012012157A (es) | 2013-02-26 |
WO2011133180A1 (en) | 2011-10-27 |
JP5907952B2 (ja) | 2016-04-26 |
KR20130064743A (ko) | 2013-06-18 |
US20100267643A1 (en) | 2010-10-21 |
CN102946885B (zh) | 2016-06-22 |
SG184935A1 (en) | 2012-11-29 |
US9901551B2 (en) | 2018-02-27 |
IL222586A0 (en) | 2012-12-31 |
CN102946885A (zh) | 2013-02-27 |
EP2560660A1 (en) | 2013-02-27 |
CN106039313A (zh) | 2016-10-26 |
AR078678A1 (es) | 2011-11-23 |
SG10201503098PA (en) | 2015-06-29 |
EP2560660A4 (en) | 2013-11-20 |
ZA201208277B (en) | 2014-05-28 |
CA2800470A1 (en) | 2011-10-27 |
SG10201909796PA (en) | 2019-11-28 |
BR112012026838A2 (pt) | 2016-07-12 |
JP2013525349A (ja) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201270767A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
EA201101524A1 (ru) | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором | |
TN2015000283A1 (fr) | Functionalized exendin-4 derivatives | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
EA201370154A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
EA201071169A1 (ru) | ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3 | |
WO2014176128A3 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
EA201201357A1 (ru) | Антитела к cd40 | |
EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
EA201491617A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
EA201391507A1 (ru) | АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
EA201370081A1 (ru) | Антитела к cd48 и их применение | |
EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
TN2014000513A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
EA201591404A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
EA201291180A1 (ru) | Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) |